Herring, L Y
Stevinson, C
Carter, P
Biddle, S J H
Bowrey, D
Sutton, C
Davies, M J
Article History
Received: 23 September 2016
Revised: 30 January 2017
Accepted: 10 February 2017
First Online: 6 March 2017
Competing interests
: Professor MJD has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp and Dohme, Boehringer Ingelheim, AstraZeneca and Janssen and as a speaker for Mitsubishi Tanabe Pharma Corporation. She has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis and Lilly. Professor SJHB reports that funding has been received since 2013 for consultancy work from Fitness First, Nuffield Health and Unilever. None of these are currently active. Funding was received in 2016 for consultancy work for Halpern Limited. In-kind support through the provision of a sit-to-stand desk was provided by Ergotron from 2012 to 2014. Advice has been requested by and offered to Active Working, Get Britain Standing and Bluearth, none with funding. DJB reports grants and non-financial support from Fresenius-Kabi, non-financial support from Nutricia, outside the submitted work. The other authors declare no conflict of interest.